- Unfortunately there are no upcoming events at this time
Soukarieh, Fadi; Liu, Ruiling; Romero, Manuel; Roberston, Shaun N.; Richardson, William; Lucanto, Simone; Oton, Eduard Vico; Qudus, Naim Ruhul; Mashabi, Alaa; Grossman, Scott; Ali, Sadiqur; Sou, Tomás; Kukavica-Ibrulj, Irena; Levesque, Roger C.; Bergström, Christel; Halliday, Nigel; Mistry, Shailesh N.; Emsley, Jonas; Heeb, Stephan; Williams, Paul; Camara, Miguel; Stocks, Michael J.
Hit Identification of New Potent PqsR Antagonists as Inhibitors of Quorum Sensing in Planktonic and Biofilm Grown Pseudomonas aeruginosa
Antonescu, Irina E.; Karlgren, Maria; Pedersen, Maria L.; Simoff, Ivailo; Bergström, Christel; Neuhoff, Sibylle; Artursson, Per; Steffansen, Bente; Nielsen, Carsten Uhd
Acamprosate Is a Substrate of the Human Organic Anion Transporter (OAT) 1 without OAT3 Inhibitory Properties: Implications for Renal Acamprosate Secretion and Drug-Drug Interactions
Sou, Tomás; Kukavica-Ibrulj, Irena; Levesque, Roger C.; Friberg, Lena; Bergström, Christel
Model-Informed Drug Development in Pulmonary Delivery: Semimechanistic Pharmacokinetic-Pharmacodynamic Modeling for Evaluation of Treatments against Chronic Pseudomonas aeruginosa Lung Infections
We have a strong interest in understanding the molecular reasons resulting in a poor aqueous solubility and have established tools for computational pharmaceutics that guide the formulation scientists in successful development pathways for a particular compound. We are currently developing a virtual intestine to enable evaluation optimization of new dosage forms in the computer rather than making use of lengthy experiments or animal studies.
Our research in the field of poorly soluble compounds is extensively based on drug dissolution & permeation studies to predict e.g. intestinal solubility. The research team also focuses on the development of sophisticated dosage forms that transforms problematic compounds (poorly soluble, biologics) into well-functioning oral medications.
Enabling formulations making use of lipid-based formulations, amorphous materials, mesoporous carriers and functionalized drug carriers are currently being explored. Additive manufacturing and 3D printing to produce personalized medicines to improve treatment and quality of life of severely sick children is one of our main targets.